SCHEMBL18153349

SCHEMBL18153349

CC(C)(C)OC(=O)N1CCN(c2nc(Cl)cc(N3CCN(C(=O)OCc4ccccc4)CC3)n2)CC1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.52
TLR9 Q9NR96 3/20 0.50
TLR7 Q9NYK1 2/20 0.50
SLC2A1 P11166 1/20 0.49
CKS1B P61024 2/20 0.48
SKP1 P63208 2/20 0.48
SKP2 Q13309 2/20 0.48
GPR119 Q8TDV5 5/20 0.47
GBA1 P04062 1/20 0.46
PRMT5 O14744 1/20 0.46
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
NAPEPLD Q6IQ20 1/20 0.44
BACE1 P56817 1/20 0.44
PTPN11 Q06124 1/20 0.44
PARP1 P09874 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24851452 0.87 CKS1B (0.49) ACHECKS1BSKP1SKP2GPR119
SCHEMBL30162245 0.87 CKS1B (0.49) ACHECKS1BSKP1SKP2GPR119
SCHEMBL13668838 0.85 MEN1 (0.53) MEN1KMT2A
SCHEMBL18153359 0.83 GBA1 (0.51) CKS1BSKP1SKP2GPR119GBA1
SCHEMBL24851765 0.83 GBA1 (0.51) CKS1BSKP1SKP2GPR119GBA1
SCHEMBL18162447 0.82 GBA1 (0.50) CKS1BSKP1SKP2GPR119GBA1
SCHEMBL24851167 0.82 GBA1 (0.50) CKS1BSKP1SKP2GPR119GBA1
SCHEMBL18153363 0.82 MEN1 (0.50) MEN1KMT2ANAPEPLD
SCHEMBL30162196 0.82 GBA1 (0.50) CKS1BSKP1SKP2GPR119GBA1
SCHEMBL18153351 0.82 ACHE (0.52) ACHETLR9TLR7SLC2A1CKS1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3283472-B1 HEPATITIS B VIRAL ASSEMBLY EFFECTORS UNIV INDIANA RES & TECH CORP (US) 2021-04-14 EP disclosed
US-20180099952-A1 HEPATITIS B VIRAL ASSEMBLY EFFECTORS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2018-04-12 US disclosed
EP-3283472-A1 HEPATITIS B VIRAL ASSEMBLY EFFECTORS Indiana University Research&Technology Corporation (US) 2018-02-21 EP disclosed
WO-2016168619-A1 HEPATITIS B VIRAL ASSEMBLY EFFECTORS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2016-10-20 WO disclosed
WO-2016168619-A1 HEPATITIS B VIRAL ASSEMBLY EFFECTORS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2016-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180099952-A1 HEPATITIS B VIRAL ASSEMBLY EFFECTORS HAVCR2, MAVS, HCCS ACHE 3524/4885TLR9 1136/4885TLR7 1287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.